A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease.

The potential efficacy of oral l-deprenyl (5 mg b.i.d.) added to the regimen of 10 patients with Alzheimer's disease receiving either tacrine or physostigmine was assessed in a double-blind, placebo-controlled, 4-week, two-period crossover pilot study. l-Deprenyl was associated with significant improvement in scores on the cognitive subscale of the Alzheimer's Disease Assessment Scale, suggesting possible additive effects of l-deprenyl to the effects of cholinesterase inhibitors.

RCT Entities:   Population Interventions Outcomes